GSK

Our CEO Emma Walmsley shares our performance in 2024, outlining our strong sales, significant R&D progress, increased returns to shareholders and further improvement to long-term growth outlook. More information for media and investors: https://gsk.to/4aO5ozt $GSK #FYResults #Earnings

We have announced our strong 2024 performance, with further improvement to our long-term outlook. Insights and information for media and investors: https://gsk.to/40Ntrda $GSK #earnings

This #WorldCancerDay, we reflect on the progress made in cancer research and look toward a future of new innovations. In partnership with CNN International Commercial, we’re sharing more about how we’re exploring targeted approaches to therapy to improve outcomes for people living with cancer. Read the full article to learn more about targeted therapy: https://gsk.me/40MVc5B

Speed and precision are key when treating cancer, because time and accuracy matter for patients. Innovative technologies, like artificial intelligence (AI) and machine learning (ML), can analyse large amounts of data faster than ever before, helping bring the right treatments to the right patients quicker and more effectively. As we approach #WorldCancerDay, Zeshaan Rasheed, Eric Richards and Anna Pastò explain how advanced technology is making a real difference for people living with cancer: https://gsk.me/40R6vuO

On #WorldNTDDay, we’re coming together with the global neglected tropical disease (NTD) community to acknowledge the vital role of partnerships in the fight against NTDs. Since last year, we’ve reached the milestone of donating 12 billion tablets of albendazole. This support has played a crucial role in combating lymphatic filariasis (LF) and soil-transmitted helminthiasis (STH) in endemic countries like Tanzania, Malawi, Zimbabwe, and many others. In 2024, the power of collaboration within the NTD community led to the elimination of LF in three more countries: Bangladesh, Lao PDR, and Timor Leste. Yet challenges still remain. The potential impact of climate change on NTDs could hinder progress and the need for continued investment is vital to support global elimination goals. This is why we remain steadfast in our pledge to donate medicines until LF is eradicated as a public health concern globally and to provide STH treatment until 2030. Together, we're working towards an NTD-free future. Thank you to all our partners, organisations, governments, and communities for your dedication. Let's continue to #UniteActEliminate.

We’re committed to protecting children from preventable childhood diseases. It's alarming to see that 2.1 million children in Nigeria and nearly 1 million in Ethiopia are missing out on routine vaccinations.     Thanks to Save the Children UK’s Immunisation Accelerator, funded by GSK, two exciting projects aimed at understanding the barriers and enhancing immunisation coverage amongst children will be awarded up to $100,000 each to further their work.     The Centre for Integrated Health Programs (CIHP) will tackle vaccine hesitancy in Northern Nigeria, while HABTech Solutions will focus on integrating health data to improve decision-making for hard-to-reach communities in Ethiopia.     These projects have the potential to transform health outcomes for children and bring us closer to a world where no child suffers from a vaccine-preventable disease. Read more: https://lnkd.in/exXcipeu    #ChangeTheTrajectory 

#News for #investors and #media: Submissions made to Chinese and Japanese health authorities for use of one of our pipeline biologics in two indications: asthma with type 2 inflammation and also CRSwNP. Learn more here: https://gsk.to/3PRrwPs

#News for #investors and #media: Today we have announced that the EMA has accepted the marketing authorisation application for use of one of our pipeline biologics in two indications: asthma with type 2 inflammation and also CRSwNP. Learn more here: https://gsk.me/3PZChPL

January has begun for us with a tremendous amount of energy and opportunities. Quickly on the heels of #JPM25, I’m excited to share another exciting update. Earlier today, we announced a multiyear research collaboration between GSK and the University of Oxford. The GSK-Oxford Cancer Immuno-Prevention Programme will focus on translational research and explore precancer biology, this in turn will help generate key insights on how cancer develops in humans, which could potentially inform new approaches to cancer vaccination and therapeutics, especially in early stages of disease and premalignant states. As we continue to grow our Oncology R&D pipeline, the impact of research collaborations such as these are profound and multifaced, fueling innovation, enhancing research capabilities, and ultimately improving patient outcomes. This collaboration demonstrates a step forward in cancer vaccine research and complements GSK’s expertise in the science of the immune system and oncology translational research. As we embark on the next chapter of the oncology journey, I look forward to the endless possibilities that lie ahead and future collaborations with our key scientific partners that can help achieve promising advances for the patients that we serve. More to come... Tony Wood Chris Sheldon, PhD Kenneth W. Hance, PhD, MPH Ramon Kemp Jamila Louahed Tim Clay Hoyin Lam, PhD Timothy Egan Garrett Rhyasen, PhD Paul Stockman Zeshaan Rasheed Carsten Goessl Tony Ng Sarah Blagden

We’re announcing a new research collaboration with University of Oxford to advance our understanding of how cancer develops. The Oxford-GSK Cancer Immuno-Prevention Programme will combine our expertise in the science of the immune system with Oxford’s cutting-edge research capabilities to explore the potential of cancer prevention through vaccination. 🔗 https://gsk.to/4hbWIFc